Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Centhaquine - Midwestern University/Pharmazz

Next Previous
Drug Profile

Centhaquine - Midwestern University/Pharmazz

Alternative Names: Centhaquin - Midwestern University/Pharmazz; Centhaquine citrate; Lyfaquin; PMZ 2010; PMZ-2010 citrate

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Midwestern University; Pharmazz
  • Developer Pharmazz
  • Class Analgesics; Antihaemorrhagics; Antihypertensives; Cardiovascular therapies; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypovolaemic shock
  • Phase III Stroke
  • Phase II Septic shock
  • Phase I Acute kidney injury; SARS-CoV-2 acute respiratory disease
  • No development reported Heart arrest; Postoperative pain

Most Recent Events

  • 22 Mar 2024 Dr. Reddy's Laboratories Limited in-licenses Centhaquine from Pharmazz
  • 22 Jun 2023 Pharmazz plans phase III clinical trial in Hypovolaemic shock (In adults, In elderly) in October 2023 (IV) (NCT05251181)
  • 28 Aug 2022 No recent reports of development identified for phase-I development in Heart-arrest in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top